In this edition, reduction efforts prevent 3.8 million lung cancer deaths since 1970, first-line combination should be ‘new standard’ in advanced lung cancer and more.

Read the full coverage here:

Smoking cessation, reduction efforts prevent 3.8 million lung cancer deaths since 1970

First-line combination should be ‘new standard’ in advanced lung cancer

Only 1 in 5 people treated with immune checkpoint inhibitors respond to therapy

‘It can save their lives’: Annual lung cancer screening improves cancer detection rate

‘Are we giving false hope?’: Few hospitalized people with cancer benefit from immunotherapy

References:

Haslam A, et al. Int J Cancer. 2025;doi:10.1002/ijc.35347.

Islami F, et al. CA Cancer J Clin. 2025;doi:10.3322/caac.70005.

Kim RY, et al. JAMA Netw Open. 2025;doi:10.1001/jamanetworkopen.2025.0942.

Riaz F, et al. JCO Oncol Pract. 2025;doi:10.1200/OP-24-00788.

Yang JCH, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC. Presented at: European Lung Cancer Congress; March 26-29, 2025; Paris.